image

Investors

Corporate Profile

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

Filing date Description Form View

Statement of changes in beneficial ownership of securities

4 View HTML

Statement of changes in beneficial ownership of securities

4 View HTML

Statement of changes in beneficial ownership of securities

4 View HTML

POS EX    

POS EX View HTML

Form of prospectus disclosing information facts events covered in both forms 424B1 424B3

424B4 View HTML

EFFECT

EFFECT View HTML

Registration statement for face-amount certificate companies

S-1 View HTML

Statement of changes in beneficial ownership of securities

4 View HTML

CORRESP

CORRESP View HTML

CORRESP

CORRESP View HTML

Data provided by Kaleidoscope.